Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Point and Figure Charting -- Ignore unavailable to you. Want to Upgrade?

To: Ms. X who wrote (21025)	6/10/1999 5:09:00 PM
From: Bwe	Read Replies (1) \| Respond to of 34811

With regard to the Drug stocks..... From the May 14th isssue of Investor's Intelligence: "In the last few weeks, we have seen RS Sells in Glaxo, Eli Lilly, Merck and Pfizer. Pfizer went on an RS Buy 10/94 at an adjusted price of $17. It had a p/e of 15.5 and a yield of 2.9% compared to the current p/e of 50 and a yield of 0.7%. Lilly's buy, at a split adjusted $15, came a month after PFE's signal. P/E was 12.9 and yield was 4.4%. Now p/e is 36.6 and yield 1.1%. It looks like the popularity in the drug group is over for a while." *With the permission of Chartcarft, Inc. Bruce